Genocea Biosciences (GNCA) Tops Q4 EPS by 5c

Genocea Biosciences (NASDAQ: GNCA) reported Q4 EPS of ($0.34), $0.05 better than the analyst estimate of ($0.39).

“Genocea made critical scientific and clinical progress in the last quarter,” said Chip Clark, President and Chief Executive Officer, Genocea. “The discovery and understanding of inhibigens has the potential to transform the process of antigen discovery for cancer immunotherapies, and even the therapeutic landscape for cancer. The GEN-009 immunogenicity results are unprecedented in neoantigen vaccines. Meanwhile, GEN-011 is progressing rapidly toward the clinic. We look forward to continuing - and capitalizing on - this strong progress in 2020.”

Genocea also appointed Gisela Schwab, M.D., President, Product Development and Medical Affairs and Chief Medical Officer of Exelixis to its board of directors effective February 14, 2020. “I am delighted to welcome Gisela to our board. Her broad oncology drug development expertise and her proven company-building track record will provide us valued counsel and insights in the coming years,” said Clark.

For earnings history and earnings-related data on Genocea Biosciences (GNCA) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Vivos Therapeutics posts 35% revenue gain but widens net loss
• Movano (MOVE) Misses Q2 EPS by 195c